Video Programs

Robert J. Motzer, MD, shares his insights on the future of treatment for advanced renal cell carcinoma.

Dr Motzer discusses data from the CLEAR trial that were presented at ASCO 2021.

An expert explains the impact of the CLEAR trial on clinical practice and reviews NCCN guidelines for the management of advanced renal cell carcinoma.

Dr Robert J. Motzer introduces data from the phase 3 CLEAR trial, which investigated lenvatinib plus pembrolizumab or everolimus for the treatment of advanced renal cell carcinoma.

Robert J. Motzer, MD, gives a background on the current first-line therapy options for advanced renal cell carcinoma, including challenges and unmet needs.

A thought leader in hematology oncology highlights therapies currently in development for the management of CLL and provides closing remarks on unmet needs regarding patients who are double-refractory.

Jeff Sharman, MD, shares insight into best practices for monitoring and managing adverse effects of treatment in chronic lymphocytic leukemia including elevated liver function tests, diarrhea, and pneumocystis pneumonia.

An expert in the management of chronic lymphocytic leukemia discusses how patient- and disease-related factors influence treatment decisions after relapse.

A key opinion leader in hematology oncology provides an overview of treatment options for patients with newly diagnosed CLL and discusses factors to consider when monitoring patients for disease relapse.

Expert hematologist/oncologists provide thoughts on the potential role of PI3K inhibitors in managing R/R FL and MZL, as well as other diseases.

Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, discuss the role of PI3K inhibitor combination therapy and novel agents on the horizon for the treatment of R/R FL and MZL.

Stephen Oh, MD, PhD, discusses the nuances of identifying disease progression vs transformation in patients with essential thrombocythemia.

Experts in essential thrombocythemia review first line treatment options.

Ruben Mesa, MD, and panel discuss the role of molecular profile in treatment decision-making.

Experts in essential thrombocythemia discuss approaches to individualizing therapy.

Dr Stephen Oh discusses risk assessment in patients with essential thrombocythemia.

Stephen Oh, MD, PhD, reviews the case of a 46-year-old female with essential thrombocythemia.

Experts in hematology/oncology review data from the UNITY-NHL trial and share insights on the sequencing of therapies in R/R FL and MZL.

Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review the tolerability and efficacy of umbralisib in the management of R/R FL and MZL.

Expert hematologist/oncologists comment on the safety profile of PI3K inhibitors when treating R/R FL and MZL and share their approach to managing associated adverse events.

Ian W. Flinn, MD, PhD, and Jason M. Melear, MD, review clinical trial data for idelalisib, copanlisib, and duvelisib and discuss their personal experience using these agents for the management of R/R FL and MZL.

Looking ahead, Loretta Nastoupil, MD, reviews the future direction and unmet needs in the management of relapsed/refractory follicular lymphoma (R/R FL).

Dr Loretta Nastoupil describes best practices for managing the side effects of tazemetostat in patients with R/R FL.

Loretta Nastoupil, MD, discusses the use of tazemetostat in patients with and without an EZH2m.

Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.

Loretta Nastoupil, MD, describes the challenges of selecting treatment beyond the second-line.

A key opinion leader in the treatment of FL provides insight on the decision of whether to add maintenance therapy to the treatment regimen.

Loretta Nastoupil, MD, discusses first-line therapy options for patients with newly diagnosed follicular lymphoma (ND FL).